Transient receptor potential vanillin 4 (TRPV4), discovered in 2000, is a poly-modeactivated Ca 2+ permeable cation channel crucial for osmotic and mechanical signal transduction, and recent research links it to neuro-muscular and skeletal diseases, making it an essential drug target . Rheumatoid Arthritis (RA), a chronic autoimmune disorder characterized by progressive synovitis and joint deterioration, affects about 246.6 per 100,000 individuals and is a leading cause of joint-related disability . Despite various synthetic and biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs), many patients remain unresponsive , necessitating new therapeutic targets. Given TRPV4's significant role in articular pain and inflammation, it represents a promising candidate for RA treatment, potentially offering safer, more effective, and convenient options for managing this debilitating condition.